Civet BioSciences is advancing the field of microbiome research in Asia through international partnerships and local discovery and development. An innovative biotechnology company based in Hong Kong, Civet is assembling a world-class team of scientists and clinicians to take a multi-faceted approach to understanding the microbiome and human health.
Civet BioSciences is dedicated to partnering with scientists and academics...
Setting up Asia's first human microbiota repository There are trillions of...
HMT therapy Scientists have uncovered the use of Human Microbiota Transfer...
what we do
Digestive Disease Research
Human Gut Project, Hong Kong
Longevity village study
Probiotics as Therapeutics
Health screening diagnostics
Civet Biosciences has a team of international and local scientific advisors, clinical trial investigators and doctors who help lead our R&D and new technology development.
For each Civet target, we look for collaboration partners and work alongside Universities, clinics, hospitals, private labs and corporations with similar focuses.
Dr. Alex Ng serves as the China Deputy Director of Health, Innovation and Partnership for the Bill & Melinda Gates Foundation. Dr. Alexander Ng leads a team that works to build health partnerships with key stakeholders in China, including the Chinese government, the private sector and global health actors. Their aim is to identify, develop and deliver high-quality, low-cost health products for use in developing countries, in order to tackle endemic diseases and other urgent health needs. Alex’s team also works with local partners to design and deliver programs that address domestic health challenges such as TB.
Alex joined the foundation in 2015 after 9 years at McKinsey & Co., where he was an Associate Partner. From 2011 to 2015 Alex co-led McKinsey’s Healthcare System & Services Practice and Corporate Finance Practice in China, where he served public, private and social sector clients on strategy, health system reform, operations transformation and investments.
Alex completed his undergraduate and medical studies at the University of Auckland, New Zealand, and a postgraduate diploma in Health Informatics at the University of Otago, New Zealand. From 2004 to 2005 he served as Chief Resident at Auckland’s Middlemore Hospital, before beginning an MPH in Health Policy and Management at the Harvard School of Public Health which he completed in 2006.
Since 2010, Alex has served as Honorary Assistant Professor of the School of Public Health at the University of Hong Kong and he has also been a Council Member of Hong Kong Council of Smoking and Health since 2012.
Dr. Jason Mann is Managing Director of ProMed Advisors, is focused on investing and building international healthcare businesses. He has a particular experience in Asia healthcare and global biotech/ medtech, with additional experience in diagnostics, healthcare IT and services. In this capacity Jason serves as Managing Director, China for International Hospitals Group (IHG), the most experienced international healthcare services company in the world. IHG has successfully completed over 480 healthcare projects in 52 countries for private and public sector clients including 24 national Governments, the United Nations, the World Bank and the International Finance Corporation. IHG recently executed a deal with Wanda Group to develop international-standard hospitals in China.
Prior, Jason was Head of China Healthcare Equity Research at Barclays, advising the largest healthcare investors on opportunities in China. He also worked as Senior Director at SciClone Pharmaceuticals, the largest China-focused U.S. therapeutics company, and advised senior management as a Consultant in the biopharma and health care sectors at McKinsey & Company. He is a frequent conference speaker and trusted expert sought by the media, with quotes in respected outlets such as Bloomberg Businessweek, Reuters, Bloomberg News, the Financial Times, The Economist Intelligence Unit, BBC television and The Wall Street Journal. Jason earned a medical degree and Ph.D. from Vanderbilt University, as well as an undergraduate degree from Harvard University.
Dr. Justin Cheng is our commercial advisor and is recognised in corporate healthcare consulting, insurance coverage and administration, quality and safety and clinical risk management. He worked regionally in Singapore, Beijing and Hong Kong for an international healthcare management company and served 88% of Fortune top 100 companies. He was the Medical Director of a leading medical group in Hong Kong and supported hundreds of full time and network doctors, and led the Clinical Governance and Central Pharmacy teams of fifty staffs including Nurses, Pharmacists and Dispensers. He is experienced in setting up clinics in Beijing and hospital redevelopment in Shenzhen. Dr. Cheng is the Founding Member of Hong Kong Professional and Senior Executives Association and involved in drafting healthcare and insurance policy recommendations to HKSAR Government. He is the Chairman a renowned UK business school alumni association where he obtained his MBA with merit and a mentor for numerous entrepreneurial start-ups. He is a surveyor for an international accreditation body for the quality and safety of over 90% of public and private hospitals in Hong Kong. He is a faculty member of a medical indemnity organisation and in the past six years trained over 900 doctors on communication skills and clinical risk management. He is the co-author of the Hong Kong Medical Association Risk Management Handbook which is a desktop reference for many clinicians in Hong Kong.
Dr Ilan Youngster MD, MMSc, has a MD from Ben-Gurion University in 2005 and subsequently completed his training in Pediatrics at Assaf Harofeh Medical Center. Between 2011 and 2015 he completed a fellowship in Infectious Diseases at Boston Children’s Hospital, one of the worlds’ leading institutions in pediatrics. During that period Ilan completed a Master’s degree in research methodology at Harvard Medical School, and became immersed in the clinical aspects of gut microbiota in health and disease. He led several translational studies examining the safety and efficacy of fecal transplants as a treatment for Clostridium difficile and was the pioneer in developing an orally administered formulation, thus making the procedure safer and more accessible to patients in need. His studies have been published in leading medical Journals including Clinical Infectious Diseases and JAMA.